

# Christine Hunt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5685906/publications.pdf>

Version: 2024-02-01

35  
papers

2,497  
citations

361413

20  
h-index

377865

34  
g-index

37  
all docs

37  
docs citations

37  
times ranked

2716  
citing authors

#	ARTICLE	IF	CITATIONS
1	Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort. <i>Gut</i> , 2022, 71, 1447-1450.	12.1	3
2	<i>APOL1</i> Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program. <i>JAMA Internal Medicine</i> , 2022, 182, 386.	5.1	31
3	Hepatitis B Virus-related Care Quality in Patients With Hepatitis B/Human Immunodeficiency Virus Coinfection Versus Hepatitis B Monoinfection: A National Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 1529-1536.	5.8	3
4	Identifying and Treating Nonalcoholic Fatty Liver Disease. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2019, 36, 20-29.	0.6	1
5	Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both?. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2019, 36, 64-71.	0.6	19
6	Expanding our toolkit to better identify drug-induced liver injury in electronic medical records. <i>Liver International</i> , 2018, 38, 585-587.	3.9	4
7	Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury. <i>Regulatory Toxicology and Pharmacology</i> , 2018, 94, 101-107.	2.7	29
8	Editorial: diabetes, obesity and clinical inertia—the recipe for advanced NASH. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1221-1222.	3.7	0
9	Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 268-278.	3.7	33
10	Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2259-2266.	2.3	26
11	Drug rechallenge following drug-induced liver injury. <i>Hepatology</i> , 2017, 66, 646-654.	7.3	50
12	Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013. <i>Military Medicine</i> , 2016, 181, 1375-1381.	0.8	1
13	Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort. <i>Regulatory Toxicology and Pharmacology</i> , 2016, 77, 257-262.	2.7	9
14	Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO Vigibase. <i>Regulatory Toxicology and Pharmacology</i> , 2015, 72, 481-490.	2.7	46
15	Children's liver chemistries vary with age and gender and require customized pediatric reference ranges. <i>Regulatory Toxicology and Pharmacology</i> , 2015, 73, 349-355.	2.7	23
16	Age-related differences in reporting of drug-associated liver injury: Data-mining of WHO Safety Report Database. <i>Regulatory Toxicology and Pharmacology</i> , 2014, 70, 519-526.	2.7	45
17	Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. <i>Pharmacogenomics</i> , 2013, 14, 541-554.	1.3	37
18	A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 571-578.	1.9	12

#	ARTICLE	IF	CITATIONS
19	Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 190-198.	1.9	32
20	Validation of Multivariate Outlier Detection Analyses Used to Identify Potential Drug-Induced Liver Injury in Clinical Trial Populations. <i>Drug Safety</i> , 2012, 35, 865-875.	3.2	12
21	A pre-marketing ALT signal predicts post-marketing liver safety. <i>Regulatory Toxicology and Pharmacology</i> , 2012, 63, 433-439.	2.7	14
22	Case Definition and Phenotype Standardization in Drug-Induced Liver Injury. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 806-815.	4.7	773
23	The evaluation of drug rechallenge: The casopitant Phase III program. <i>Regulatory Toxicology and Pharmacology</i> , 2010, 58, 539-543.	2.7	3
24	Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: A systematic review. <i>Hepatology</i> , 2010, 52, 2216-2222.	7.3	33
25	Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in Vigibase. <i>Drug Safety</i> , 2010, 33, 503-522.	3.2	142
26	Drug-induced liver injury following positive drug rechallenge. <i>Regulatory Toxicology and Pharmacology</i> , 2009, 54, 84-90.	2.7	54
27	Co-medications That Modulate Liver Injury and Repair Influence Clinical Outcome of Acetaminophen-Associated Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 882-888.	4.4	38
28	Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease. <i>Regulatory Toxicology and Pharmacology</i> , 2008, 52, 85-88.	2.7	21
29	Clinical relevance of hepatitis B viral mutations. <i>Hepatology</i> , 2000, 31, 1037-1044.	7.3	324
30	Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial. <i>Hepatology</i> , 2000, 32, 135-138.	7.3	162
31	Liver disease in pregnancy. <i>American Family Physician</i> , 1999, 59, 829-36.	0.1	19
32	Effect of postoperative complications on health and employment following liver transplantation. <i>Clinical Transplantation</i> , 1998, 12, 99-103.	1.6	23
33	Effect of orthotopic liver transplantation on employment and health status. <i>Liver Transplantation</i> , 1996, 2, 148-153.	1.8	63
34	Effect of age and gender on the activity of human hepatic CYP3A. <i>Biochemical Pharmacology</i> , 1992, 44, 275-283.	4.4	393
35	Regulation of rat hepatic cytochrome P450IIE1 in primary monolayer hepatocyte culture. <i>Xenobiotica</i> , 1991, 21, 1621-1631.	1.1	19